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Background: Neuroblastoma is the most common solid tumour of infancy and is responsible for 15% of childhood
cancer deaths. Presence of amplified MYCN in neuroblastoma is associated with poor prognosis and rapid tumour
progression. The aim of this study was to examine and compare the ultrastructural features of high-risk MYCN
amplified neuroblastomas, with lower-risk non-MYCN amplified tumours.
Methods: This was a retrospective study evaluating archival diagnostic tissue samples, in which Fluorescence in-situ
hybridisation (FISH) had been used at diagnosis to establish MYCN status. 22 (11 MYCN amplified tumours and 11
non-MYCN amplified) tumours of similar light microscopic appearance (poorly differentiated neuroblastoma) were
then selected for ultrastructural examination.
Results: There is a relationship between ultrastructural features in neuroblastoma and MYCN status, although with
marked overlap between groups. MYCN amplified tumours generally exhibited a ‘less differentiated’ ultrastructural
phenotype, with significantly smaller neurotubules (NT) in the cell body (p < 0.002). Non-MYCN amplified tumours show
increased features of neuronal differentiation, with fewer neurosecretory granules (NSG) and NT in the cytoplasm.
Conclusions: MYCN amplification is associated with a less differentiated ultrastructural phenotype, and lack of MYCN
amplification with relative ultrastructural neuronal differentiation.
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Neuroblastoma is the most common solid tumour of
childhood, and with an incidence of 1 in 10,000, it is re-
sponsible for 15% of childhood cancer deaths [1,2]. Neuro-
blastoma originates from primordial neural crest cells,
often occurring in sympathetic ganglia and chromaffin
cells of the adrenal medulla; however it can occur any-
where along the sympathetic chain, including the pelvis,
neck and brain [3]. Neuroblastoma is classed as one of the
‘small blue round cell tumours’ and by routine light mi-
croscopy demonstrates sheets and nests of small primitive
appearing cells with speckled, hyperchromatic nuclei,
scant cytoplasm and poorly defined cell borders. The
nested background demonstrates faintly eosinophillic* Correspondence: n.sebire@ucl.ac.uk
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unless otherwise stated.fibrillary neuropil, a mass of interwoven nerve endings,
dendrites and other neurone components [4].
Prognosis can vary markedly, from fatal to spontaneous
regression [1,5]. Molecular biology findings are associated
with adverse prognosis, the best studied of which is ampli-
fication of the MYCN oncogene. MYCN is a member of
the MYC proto-oncogene family, and is a nuclear tran-
scription factor not normally found in adult tissues. [6,7].
Presence of MYCN amplification is associated with
adverse outcome and tumour progression [8,9].
Ultrastructural features of neuroblastic tumours are
well-described [10-14] but there are no data regarding ul-
trastructural findings specifically in relation to MYCN sta-
tus. This study examines the ultrastructure of high-risk
MYCN amplified neuroblastomas, compared with low-risk
non-MYCN amplified tumours to test the hypothesis
that neuroblastomas will have ultrastructural differences
related to their molecular characteristics.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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A search of the histopathology diagnostic archive was made
to identify neuroblastomas (Neuroblastic tumour, neuro-
blastoma (Schwannian stroma poor), poorly differentiated
subtype’ based on light microscopic assessment) with poten-
tially viable material stored for electron microscopic exam-
ination and MYCN status assessment performed as part of
routine clinical care. 25 MYCN amplified, and 25 matched
non-MYCN amplified, neuroblastomas were initially identi-
fied, of which 22, 11 cases in each group, were suitable for
ultrastructural analysis. Suitability was judged based on the
amount of necrosis present and tumour preservation ob-
served at ultrastructural level. The number of cases was
considered statistically significant for the study with a power
of 80% to detect differences of 25% between groups.
Samples were initially confirmed as poorly differentiated
neuroblastomas by light microscopy using 3 μm formalin
fixed paraffin embedded tissue and a Haematoxylin and
Eosin stain. Sectioning and staining were carried out by
standard methods as per standard [14]. Further confir-
mation of neuroblastoma was by the use of immunohisto-
chemistry for NB84 and CD56 [4]. Fluorescence in-situ
Hybridisation (FISH) was performed as part of routine
clinical care using a standard protocol [15]. We used a
commercial probe available from Abbott Molecular, USA,
with each new batch validated in the laboratory before use
on patient material. (Vysis LSI N-MYC (2p24) Spectrum-
Green/CEP 2 SpectrumOrange Probe (Abbott Molecular,
USA)). Cells hybridized using this dual-colour probe show
multiple green signals when MYCN amplification is
present. When investigating MYCN status by Fluorescence
In Situ Hybridization (FISH), MYCN amplification is de-
fined as >4-fold MYCN signals compared to 2p reference
probe signals. MYCN amplification can occur as either
intrachromosomal homogeneously staining regions (HSRs)
or as genetically unstable extrachromosomal double
minutes (DMs) [16].
For ultrastructural analysis, samples were fixed in 2.5%
glutaraldehyde in 0.1 M cacodylate buffer with secondary
fixation in 1.0% osmium tetroxide. Tissues were dehy-
drated in graded ethanol and transferred to propylene
oxide and finally infiltrated and embedded in Agar 100
epoxy resin. 90 nanometre ultra-thin sections were cut
using a Diatome diamond knife on a Leica Ultracut UCT
ultramicrotome. Sections were picked up on copper grids
and stained with alcoholic uranyl acetate and Reynold’s
lead citrate. The samples were then viewed with JEOL
(UK) Ltd, JEM-1400 120 kV Transmission Electron Micro-
scope. All measurements were carried out using the JEOL
microscope and Advanced Media Technologies Inc (AMT)
software and were recorded with the images. Initial obser-
vations included overall tumour architecture, cell adhesion
and stroma and subsequent quantitative observations in-
cluded the most characteristic and frequently seen featuresof neuroblasts, cytoplasmic (neuritic) processes and the
neurosecretory granules (NSG). The cell processes usually
contain neurotubules (NT), and intermediate filaments
[17]. The position of these tubules within the cell, and
whether the tubules were in the cytoplasm, or within the
processes was observed. The number and diameters (nm)
of the neurotubules (NT) present in the cell body were
measured in multiple well preserved and viable cells per
sample (total 45 measurements in the 11 MYCN amplified
group and 48 measurements in the 11 non-MYCN ampli-
fied group). NSG are small, round, membrane bound
secretory granules, which contain a characteristic central
dense core surrounded by a peripheral halo [18]. The num-
ber of NSG present in the cell body were counted and their
diameter measured. The numbers of the NSG and NT were
measured only within the cell body, as it was not possible
to track the cell processes using a 2-D plane. All diameter
measurements were carried out using the AMT software
and all measurements were in nanometres (nm).
All statistical analyses were calculated with SPSS (Statis-
tical Package for the Social Sciences), version 19.0, IBM,
UK. The parametric student T-test and the non-
parametric Mann-Whitney U test were used to compare
distributions between groups as appropriate. All results
were considered statistically significant at p < 0.05. Ethical
approval was obtained from the National Research Ethics
Service (NRES) committee London, Bloomsbury (REC re-
ference number 11/LO/1175). Approval was gained from
Great Ormond Street NHS Hospital Foundation Trust
and Institute of Child Health (UCL) (R&D number
10MH31) and the study was funded by Great Ormond
Street Children’s Charity (V0907). All cases used were
non-identifiable, archival cases.
Results
The mean median age of patients across both groups was
27 (range 1-144) months, with no significant difference in
age between the MYCN amplified and non-amplified
groups (P = 0.55). Ultrastructural morphological examin-
ation demonstrated that MYCN amplified tumours had a
subjectively ‘less differentiated’ ultrastructural appearance,
with scanty neuritic processes, which contained fewer
NSG and NT. The non-MYCN amplified tumours had a
more differentiated ultrastructural appearance, with fre-
quent cell processes all appearing well developed with
abundant NSG and NT, (Figures 1 and 2).
There were significantly fewer NSG and NT in the cell
body of the non-MYCN amplified neuroblastomas, but
with markedly overlapping distributions. The mean num-
ber of NSG in the cell body was 6.4/cell for the MYCN
amplified group versus 4.1/cell for the non-MYCN ampli-
fied group (P < 0.001). The mean number of NT in the cell
body of the MYCN amplified group was 21.8/ cell com-
pared to a mean of 17.7/cell for the non- MYCN amplified
Figure 1 Photomicrographs of MYCN amplified neuroblastoma
demonstrating: A. Poorly differentiated neuroblasts with irregular
nuclear outline and moderately sized nucleoli. The cytoplasm is scant
and contains a few mitochondria and numerous polyribosomes with
no evidence of cell junctions. Neuritic (cytoplasmic) processes are
sparse and occasional neurosecretory granules are present in the cell
cytoplasm. Original magnification ×1500. B. Rudimentary neurites are
present in this area of the micrograph with numerous microtubules
but no neurosecretory granules, emphasising the lack of differentiation.
Often solitary mitochondria are also seen in the cytoplasmic process.
Original magnification ×5000. C. Higher magnification shows
microtubules in transverse and longitudinal orientation. Their mean
diameter was 22.5 nm. Original magnification ×25000.
Figure 2 Photomicrographs of non-MYCN amplified
neuroblastoma demonstrating: A. Neuroblastoma with
widespread neuritic processes. Tumour cells are small and round
and do not show ganglion cell differentiation at this stage.
Original magnification ×1000. B. The image demonstrates
abundant sheaves of microtubules and neurites in transverse
section with many electron dense neurosecretory granules.
Original magnification ×3000. C. A high power view of a neurite
process with dense-core, neurosecretory granules with a characteristic
peripheral halo. The mean diameter of the granules in all cases was
98 nm. Original magnification ×15000.
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nificantly different between groups. (P = 0.88), mean diam-
eter of all cases, 98 nm. However, the mean diameter ofNT in the MYCN amplified group was significantly less
than the non-MYCN amplified group (22.5 nm versus
23.8 nm respectively (P < 0.002) (Figure 3).
Figure 3 Box-whisker plots demonstrating distribution of number of neurotublues (NO NT) and number of neurosecretory granules (NO NSG)
per cell examined in MYCN amplified (AMP) versus non-MYCN amplified (NON) morphologically poorly differentiated neuroblastomas.
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The findings of this study have demonstrated that there
are significant ultrastructural morphological differences
between MYCN-amplified and non-MYCN-amplifiedneuroblastomas, including a statistically significant re-
duction in diameter of NT, and significantly more NSG
and NT in the cell body of MYCN-amplified tumours.
These differences may be explained by the finding that
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therefore the NSG and NT in the cell bodies have not yet
extended into cell processes. Additionally, since MYCN-
amplified tumours appear less differentiated, the smaller
size of their NT may represent tubules in these tumours
being less well-developed.
MYCN is involved in the expression of many target
genes, which regulate a range of cellular processes, includ-
ing cell growth, proliferation, differentiation, and apoptosis
[19]. MYCN is primarily an embryonic developmental
gene, whose normal expression is specifically restricted (in
humans and mice) to certain tissues in the developing em-
bryo. MYCN is specifically found in the neuroepithelium,
and also in the developing lung, heart kidney and intestine
[7,20]. Primary functions of MYCN are proposed to be re-
lated to control of cell proliferation and enabling cells to
remain in relatively undifferentiated states [19]. Over ex-
pression of MYCN in the neural crest results in an in-
creased generation of neurons but down regulation of
MYCN is required for these neurons to become terminally
differentiated [21,22]. In combination, these findings sug-
gest that MYCN signalling is important in maintaining
cells in an undifferentiated state and that down regulation
of MYCN can lead to neuronal differentiation [6]. The
present ultrastructural findings support these suggested
roles since MYCN amplified cells had a morphologically
less differentiated appearance, with associated morpho-
metric changes.
Increased MYCN expression keeps cells in an undiffer-
entiated and proliferative state [6]. Therefore, the hypoth-
esis has been raised that blocking MYCN expression or its
action could lead to less aggressive tumours, and lead to
new therapies for high-risk patients [23]. Differentiation as
a target for therapy has been investigated and several
groups are attempting to down regulateMYCN expression
as a treatment in high-risk MYCN amplified neuroblast-
oma. Several agents have been investigated, of which 13-
cis-retinoic acid shows the most promise, showing neurite
outgrowth and differentiation of human neuroblastoma
cells in vitro and in vivo [6]. These results are in accord-
ance with the current ultrastructural findings, that lower-
risk tumours show substantial neurite outgrowth and were
morphologically more differentiated, despite being within
the poorly differentiated light microscopy subgroup of
neuroblastomas.
The present study demonstrated a significant difference
in both the size and number of neurotubules withinMYCN
amplified tumours compared to the non-MYCN amplified
tumours, which has not been reported previously. Microtu-
bules and intermediate filaments, of which neurotubules
are an example, are involved in intracellular transport and
it can be hypothesised that if a cell has a more patent net-
work of tubules and filaments then drug transport may
occur more efficiently. This remains entirely speculativebut may offer a possible explanation regarding the associ-
ation ofMYCN amplified tumours with adverse outcome.
Whilst markers of differentiation, such as dense core
neurosecretory granules and neuritic processes, may be
identified, and the neuropil seen on light microscopy is
identified as neuritic processes with NSG, poorly differen-
tiated neuroblastomas have previously been reported to
generally show no major ultrastructural variations related
to outcome not identified by light microscopy, although
there may be an association between low numbers of NSG
and adverse clinical course [10-13].
Conclusions
There are ultrastructural morphological differences in
neuroblastoma, dependent upon MYCN amplification sta-
tus. The data is limited by the small study size but pro-
vides the first data in this area, and is consistent with
current evidence on functioning of MYCN, with increased
MYCN expression being associated with a less differenti-
ated phenotype.
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